This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sagent Pharmaceuticals Appoints James M. Hussey As President

SCHAUMBURG, Ill., March 19, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that its Board of Directors has appointed James M. Hussey as its President, effective March 25, 2013. Mr. Hussey, 53, will be responsible for Sagent's commercial operations, including development, regulatory and supply chain activities, as well as having primary responsibility over the Company's sales, marketing and human resources functions.

"We are delighted to have Jim join the organization as our president," said Jeffrey M. Yordon, chief executive officer and chairman of the board of Sagent. "Given the growth trajectory we have experienced and our projected performance going forward, we want to provide seasoned leadership to our commercial operations while I continue to drive strategic development, develop partner relationships and investigate vertical integration. Jim has significant industry experience and knowledge of specialty pharmaceuticals and is a great addition to our leadership team. We look forward to his contributions as we move forward."

Mr. Hussey stated, "I'm pleased to be joining the Sagent team, which has established a track record of success in the injectable pharmaceuticals market using a unique business model.  I look forward to playing an instrumental role in executing our strategic objectives to drive future growth and long-term profitability."

Hussey has over 25 years of experience in the pharmaceutical and healthcare industries with experience in both large Pharma and emerging start-ups, most recently with NanoInk, a privately held Nanolithography company, where he served as chief executive officer and Ovation Pharmaceuticals, a privately held pharmaceutical company, where he served as vice president of strategic planning. Prior to his career with Ovation, Hussey worked for NeoPharm, Inc., Physician Quality Care, Inc. and Bristol Myers Squibb Company. In addition, Hussey has extensive board experience with start-up companies and community organizations. He earned a Bachelor's degree in Pharmacy from Butler University and an MBA from the University of Illinois at Chicago.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs